PSNL News and Press, Personalis Inc. From 08/26/21

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the Morgan Stanley 19 th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 3:30 p.m. Eastern Time. About Personalis, Inc....

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will relocate both its corporate headquarters and the Personalis Clinical Laboratory from Menlo Park to 6600 Dumbarton Circle in Fremont. The new facility will support the Company...

The following slide deck was published by Personalis, Inc. in conjunction with this event. For further details see: Personalis (PSNL) Investor Presentation - Slideshow

Personalis, Inc. (PSNL) Q2 2021 Earnings Conference Call August 04, 2021 5:30 PM ET Company Participants Caroline Corner – Investor Relations John West – President and Chief Executive Officer Aaron Tachibana – Chief Financial Officer Conference Call Participants Kevin DeG...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported financial results for the second quarter ended June 30, 2021. Second Quarter and Recent Highlights Record quarterly revenue of $21.7 million in the second qu...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the 6 th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 17, 2021. About Personalis, Inc. Personalis...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced translational genomics and diagnostics for cancer, today announced the publication of its study " Prediction of immunotherapy response in melanoma through combined modeling of neoantigen burden and immune-related resistance mec...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its second quarter 2021 financial results after the market closes on Wednesday, August 4, 2021. In conjunction with the release, the Company will host a conference call and webcast...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced its inaugural event, NeXT Level Biomarkers Symposium , which will showcase novel research into emerging biomarkers using the Personalis NeXT Platform ™. This event will detail t...

Personalis, Inc. is a global cancer genomics company offering genomic sequencing and data analytics solutions for comprehensive molecular data analysis for patient-specific cancers and immune responses. Personalis' products include: 1) ImmunoID NeXT, a universal cancer immunogenomics ...